PMC5237177_01
Patient's hemoglobin trend during hospitalization and peripartum period. Patient's hemoglobin trend during hospitalization and peripartum period shows a mild increase in hemoglobin after starting eculizumab
40164_2017_64_Fig1_HTML.jpg
PMC5237177_01_40164_2017_64_Fig1_HTML.jpg
Fig1
Despite daily plasmapheresis, the patient required multiple transfusions to maintain her hemoglobin levels above 8 (Fig. 1) and remained hypertensive requiring 2 antihypertensive medications. Her platelet count increased to 124,000/mm3 (Fig. 3), hemoglobin levels remained above 8.5 mg/dL without any transfusion (Fig. 1), and LDH trended down to 520 U/L (Fig. 4).
Patient's creatinine trend during hospitalization and peripartum period. Patient's creatinine trended down during hospitalization after starting eculizumab with a return of creatinine back to baseline in the peripartum period
40164_2017_64_Fig2_HTML.jpg
PMC5237177_01_40164_2017_64_Fig2_HTML.jpg
Fig2
Her renal function continued to worsen (Fig. 2) requiring hemodialysis on the 4th day of initiating daily plasmapheresis.
Patient's platelet count trend during hospitalization and peripartum period: Patient's platelets showed a steady increase after the patient was started on eculizumab
40164_2017_64_Fig3_HTML.jpg
PMC5237177_01_40164_2017_64_Fig3_HTML.jpg
Fig3
Her platelet count increased to 124,000/mm3 (Fig. 3), hemoglobin levels remained above 8.5 mg/dL without any transfusion (Fig. 1), and LDH trended down to 520 U/L (Fig. 4).